Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021

Marie C. D. Stoner,1 Frederick J. Angulo2 Sarah Rhea,1 Linda Morris Brown,1 Jessica E. Atwell1 Jennifer L. Nguyen2 John M. McLaughlin2 David L. Swerdlow3 and Pia D. M. MacDonald4

1RTI International, Research Triangle Park, North Carolina, USA; 2Medical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, Pennsylvania, USA; 3Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA, and 4Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina, USA

Background. Information is needed to monitor progress toward a level of population immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sufficient to disrupt viral transmission. We estimated the percentage of the US population with presumed immunity to SARS-CoV-2 due to vaccination, natural infection, or both as of August 26, 2021.

Methods. Publicly available data as of August 26, 2021, from the Centers for Disease Control and Prevention were used to calculate presumed population immunity by state. Seroprevalence data were used to estimate the percentage of the population previously infected with SARS-CoV-2, with adjustments for underreporting. Vaccination coverage data for both fully and partially vaccinated persons were used to calculate presumed immunity from vaccination. Finally, we estimated the percentage of the total population in each state with presumed immunity to SARS-CoV-2, with a sensitivity analysis to account for waning immunity, and compared these estimates with a range of population immunity thresholds.

Results. In our main analysis, which was the most optimistic scenario, presumed population immunity varied among states (43.1% to 70.6%), with 19 states with ≤60% of their population having been infected or vaccinated. Four states had presumed immunity greater than thresholds estimated to be sufficient to disrupt transmission of less infectious variants (67%), and none were greater than the threshold estimated for more infectious variants (≥78%).

Conclusions. The United States remains a distance below the threshold sufficient to disrupt viral transmission, with some states remarkably low. As more infectious variants emerge, it is critical that vaccination efforts intensify across all states and ages for which the vaccines are approved.

Keywords. COVID-19 vaccination; population immunity; SARS-CoV-2.

Closely monitoring the proportion of the population vaccinated against or previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for public health preparedness and response. As of August 22, 2021, 170.8 million people age ≥12 have been fully vaccinated, and 37.6 million coronavirus disease 2019 (COVID-19) cases have been reported in the United States [1]. Although the number of people who have both been vaccinated and had a reported COVID-19 infection is not known, vaccinated persons and those with reported infections represent 51.5% and 11.3%, respectively, of the total population [1].

In mid-2021, the Delta variant (B.1.617.2), a World Health Organization variant of concern (VOC) [2], became the predominant SARS-CoV-2 variant circulating in the United States. Associated with increased infectivity and severity [2], Delta prevalence quickly increased from <1% of cases in May 2021 to >80% of cases in July 2021 [3]. As more people are vaccinated or infected, immunity in the population will increase, approaching levels that may sufficiently slow community transmission. Population immunity, also referred to as herd immunity [3], occurs when a sufficient proportion of a community is immune to a particular disease, making it unlikely for an infected person to come into contact with someone who is susceptible and thus substantially limiting pathogen transmission [4, 5]. The level of immunity in a community that is sufficient to limit spread of a given pathogen is dependent on numerous factors, but is most simply calculated as 1 – (1/R0), where R0 is the reproductive number or a measure of the degree to which the pathogen is contagious [4, 5]. Population immunity threshold estimates for SARS-CoV-2 have ranged from 50% to 83% [6–8]. The threshold is likely even higher for variants that are more infectious than the original wild-type and therefore have a higher reproductive number; Delta
has an estimated population immunity threshold as high as 80%–90% [9, 10]. Progress toward this threshold can be affected by the timing and extent of transmission patterns in different geographic areas. Thus, it is important to estimate how many people in a population have “presumed immunity” (ie, have been infected or vaccinated) to SARS-CoV-2 to focus public health response efforts where they can achieve the biggest impact and thereby reduce risk of severe COVID-19 cases and associated deaths.

While several studies have speculated how close the United States may be to reaching SARS-CoV-2 population immunity, few have attempted to robustly calculate presumed immunity percentages by state [6, 7, 9, 11, 12]. Population immunity to SARS-CoV-2 will result from both immunity from vaccination and immunity from natural infection; however, monitoring population immunity has largely been based on vaccination rates alone. Routine surveillance data on infections and vaccinations, while imperfect, can be used to provide an estimate of progress toward various immunity thresholds by estimating the percentages of vaccinated or infected persons. These data will be dynamic, as will be the required threshold, if VOCs with different $R_0$ values continue to emerge. Therefore, it will be particularly important to continue to track this information as the pandemic progresses.

In this study, we estimated the percentage of the US population, by state, with presumed immunity to SARS-CoV-2 due to vaccination or natural infection (or a combination) as of August 26, 2021. Our study builds on other similar work through the use of seroprevalence surveys, which provide a more direct estimate of presumed immunity due to previous SARS-CoV-2 infection [12]. We used vaccination and seroprevalence survey data to derive estimates of the percentage of people who have presumed immunity due to either vaccination against COVID-19 or infection with SARS-CoV-2. To monitor progress toward population immunity, we then compared these estimates with a range of potential thresholds needed to achieve population-level immunity.

**METHODS**

Using publicly available data, we employed a 3-step process to calculate presumed population immunity by state (Figure 1). First, we calculated the percentage of the population who were presumed immune because of natural infection by using seroprevalence estimates by state and adjusting for underreporting. Second, we calculated the percentage of the population who were presumed immune because of vaccination by considering the vaccine effectiveness of being fully vaccinated (receiving the recommended doses for a COVID-19 vaccine) and being partially vaccinated (receiving only 1 dose of a 2-dose vaccine). At the time of this analysis, federal guidelines did not include recommendation for booster vaccination(s) beyond the original dosing regimen specified by the vaccine manufacturers. Third, we estimated the percentage of the population for 4 mutually exclusive categories: (1) immune because of both vaccination and infection; (2) immune because of vaccination only; (3) immune because of infection only; and (4) not immune. Categories 1–3 were combined to create a group of individuals with “presumed immunity.” Our final estimate represents the total population by state meeting criteria for this composite

![Figure 1](image-url)
category. Lastly, we compared these estimates with a range of potential values for the population immunity threshold to determine how close each state may be to achieving population immunity [6–9, 13].

To estimate the number of people previously infected with SARS-CoV-2 by state, we followed Angulo and colleagues’ methods [14]. Specifically, we obtained the most recent seroprevalence data for a given state from the Centers for Disease Control and Prevention (CDC) Nationwide Commercial Laboratory Seroprevalence Surveys, which use blood samples (eg, from routine medical care or sick visits) submitted to commercial laboratories for reasons unrelated to COVID-19 in all 50 US states, Washington DC, and Puerto Rico [1, 15, 16]. Of these blood samples, ~1300/state are tested for SARS-CoV-2 every 2 weeks [16]. At the time of our analysis, the most recent estimates were from July 31, 2021. We included estimates from tests that used only the nucleocapsid protein as the viral antigen target rather than the spike protein because the nucleocapsid is a better representation of immunity due to infection [1]. To prevent unreliable estimates, we do not report results for states with seroprevalence estimates based on <1000 samples. We multiplied the seroprevalence estimate for each state by the population of that state from the US Census [17] to derive an estimate of the number of persons infected on the date seroprevalence samples were collected. Next, we compared the estimated number of infected persons with the total number of cumulative reported infections on that date from the CDC (June 31, 2021) to calculate the underreporting multiplier for that state. If the underreporting multiplier was <1 (indicating overreporting, not underreporting, of cases), the multiplier was set at 1 for that state to equal the number of reported cases. In this case, we assumed that overreporting of cases was not that likely and that cases that were reported were real. However, most states did not have a multiplier <1. Lastly, we estimated the number of infections in the population on August 26, 2021, the most recent date at the time of analysis, by multiplying the cumulative number of infections on that day from the CDC by the underreporting multiplier. We divided this number by the total population to derive the percentage of the total population with immunity due to infection as of August 26, 2021.

To determine how many people may have presumed immunity through vaccination, we used estimates of the percent fully vaccinated and the percentage who had received at least 1 dose of a 2-dose regimen, as reported by the CDC on August 26, 2021 [1]. We calculated the percent immune from full vaccination by multiplying the total population fully vaccinated with each approved COVID-19 vaccine by the estimated protection against infection for Janssen (72% in US subsamples [18, 19]), Moderna (94% [20]), and Pfizer-BioNTech (95% [21]). We used an estimate of 85% protection for those vaccinated with an unknown COVID-19 vaccine [22]. We then calculated the number who had received only 1 dose of Moderna or Pfizer-BioNTech vaccine by subtracting those who were fully vaccinated from those with at least 1 dose and multiplied this number by estimated protection from 1 dose of a 2-dose vaccine (82%) [23]. Next, we multiplied the percentages of persons immune from full vaccination (by any type of COVID-19 vaccine) and partial vaccination by the total population and added them together. We divided this number by the total population to estimate the percentage of the total population with vaccine-derived immunity as of August 26, 2021.

To determine the percentage of the total population in each state with some immunity due to vaccination, infection, or both, we defined immunity in the population based on 4 mutually exclusive categories: immune due to both vaccination and infection, immune due to vaccination only, immune due to infection only, and not immune. We calculated the percentage of the population in each category by multiplying the percentage with some immunity due to natural infection by the percentage vaccinated, assuming independence. For example, to calculate the percentage who were both vaccinated and had immunity after natural infection, we multiplied the 2 (vaccinated % x immune %), and to calculate the percentage who were vaccinated but not immune after natural infection, we multiplied the percent vaccinated by those not immune ((percent vaccinated x (1 – (percent immune))) and so on for each of the 4 categories. The 4 categories sum to 100% of the population. Finally, we added the percentages with immunity due to both infection and immunity, infection only, and vaccination only to get the percentage of the total population of each state with some immunity due to vaccination and/or infection as of August 26, 2021.

We conducted a sensitivity analysis to explore the effect of waning immunity from natural infection and from vaccination. For waning immunity from natural infection, we used CDC data [1] on the number of reported COVID-19 cases per day to estimate the proportion of the reported infections that occurred >12 months before August 26, 2021 (ie, as of the end of August 2020), 6–12 months before August 26, 2021 (ie, as of the end of February 2021), and <6 months before August 26, 2021 [1]. For those infected during these time periods, we estimated immunity of 25%, 50%, and 100%, respectively. For waning immunity from vaccination, we used vaccine uptake data from the CDC [1] to estimate the proportion of the fully vaccinated who, as of August 26, 2021, had been fully vaccinated for ≥5 months (ie, before the end of March 2021) and <5 months (ie, after the end of March 2021) [1]. For those who had been vaccinated for ≥5 months, we assumed vaccine efficacy of 65%. Additionally, we did a second sensitivity analysis to account for the potential effect of the Delta variant on our results. Based on a paper by Tartof et al., we estimated that for fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was reduced to 73%, regardless of vaccination type [24]. Effectiveness against SARS-CoV-2 infections then declined from 73% to 47% after


≥5 months based on estimates of waning immunity due to the Delta variant [24].

The final estimate of the percentage of persons with presumed immunity due to COVID-19 vaccination or SARS-CoV-2 infection by state was compared with estimates of the population immunity threshold from the literature to assess each state's progress toward population immunity. We used a range of potential thresholds, from a minimum of 67% to a maximum of 90% based on a range of R\text{\textsubscript{0}} of the virus of 3 to 10, with the most likely number being ~3 for early variants (67%) and 4.5 for more infectious variants (78%), although the R\text{\textsubscript{0}} and corresponding threshold for the Delta variant is likely higher than 78% [6–10, 13, 25, 26]. If future VOCs arise that are more transmissible, the R\text{\textsubscript{0}} could be higher, leading to an even higher threshold.

RESULTS

As of August 26, 2021, the percentage of the total population previously infected with SARS-CoV-2 by state ranged from 4.0% in Hawaii to 41.7% in Mississippi (Figure 2). The percentage vaccinated for COVID-19 ranged from 35.5% in Idaho to 61.5% in Massachusetts. Comparisons among the 4 categories indicated that the people with immunity due to vaccination only represented the largest proportion of the population (Table 1) and ranged from 22.1% in Mississippi to 57.7% in Hawaii. In the second category, the percentage of the population with presumed immunity due to both vaccination and infection ranged from 2.4% in Hawaii to 18.1% in Illinois and 18.0% in New Jersey. The states with the highest percentages of immunity due to both infection and vaccination were those where a large percentage of the population had been previously infected (eg, 31.5% in New Jersey, 33.7% in Illinois). In the third category, the percentage with presumed immunity by infection only and not vaccination ranged from 1.6% in Hawaii to 25.9% in Mississippi. States with a high percentage of immunity due to infection only had relatively low or modest vaccination rates (eg, 37.9% in Mississippi). In the fourth category, the percentage without immunity from either vaccination or infection ranged from 29.4% in New Jersey to 56.9% in Idaho. States with the highest percentages of the population without immunity had some of the lowest vaccination rates (eg, 39.0% in West Virginia, 35.5% in Idaho). In 19 states, 240% of the population had no immunity to SARS-CoV-2.

The overall percentage of each state with presumed immunity due to either vaccination or infection ranged from 43.1% in Idaho to 70.6% in New Jersey (Figure 3). Using a minimum threshold of 67% corresponding to an R\text{\textsubscript{0}} of 3, only 4 states would have reached population immunity (New Jersey, Illinois, Maryland, Pennsylvania) [6–9, 13]. Based on a higher R\text{\textsubscript{0}} of 4.5 for more infectious variants (78% threshold), no states would have reached the population immunity threshold as of August 26, 2021 [6–9, 13]. Given that the threshold for the Delta variant is likely even higher than 78%, we can assume that no states will have reached that threshold [26].

Our main results represented the most optimistic scenario and are likely high. In the first sensitivity analysis assessing the impact of waning immunity alone, we estimated that the percentage with presumed immunity due to either vaccination or infection would be lower than originally calculated and would range from 37.9% in Idaho to 62.3% in New Jersey (Supplementary Table 1), and none of the states would meet even the minimum threshold of 67%. In the second sensitivity analysis to account for reduced vaccine effectiveness and waning immunity with the Delta variant, we estimated that the percentage with presumed immunity due to either vaccination

---

**Figure 2.** Percentage of the population (A) previously SARS-CoV-2 infected and (B) vaccinated for COVID-19 by state as of August 26, 2021. Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
or infection would range from 33.3% in Idaho to 56.2% in New Jersey (Figure 4; Supplementary Table 2).

**DISCUSSION**

We found that the estimated proportion of the population with presumed immunity to SARS-CoV-2 as of August 26, 2021, varied substantially by state in the United States. The states with the highest levels of immunity were those with the highest vaccination rates or those with modest vaccination rates but large proportions immune by infection. In our main analysis, which was the most optimistic scenario, 4 states may have reached thresholds for population immunity based on less infectious variants (67%), but we estimated that none of the states would
have reached population immunity for more infectious variants (78% or higher) as of August 26, 2021. As variants that are more infectious may continue to emerge, it is critical that we continue to monitor and intensify vaccination efforts across all states.

The number of states with a high proportion of the population with no presumed immunity to SARS-CoV-2 is high, with proportions reaching >50% in 4 states and ≥40% in 19 states. The findings with no presumed immunity to SARS-CoV-2 portend continued cases, hospitalizations, and large outbreaks of COVID-19. Further, after accounting for waning immunity and reduced vaccine effectiveness with the Delta variant, we found that presumed immunity may be even lower, which would lead to an even higher likelihood for sustained transmission than in our original calculations.

With the low levels of presumed immunity in many states, increasing the immunity of the population by vaccinating children will be important. In 2019, 14.6% of the US population was aged <12 years [27]. Achieving population immunity levels >75% for the entire population (all ages) will be difficult without achieving substantial immunity in children.

There were several limitations to our approach. First, we used data from the CDC’s Nationwide Commercial Laboratory Seroprevalence Surveys because they provide nucleocapsid seroprevalence estimates for each state. As these surveys use blood samples submitted for reasons unrelated to COVID-19 (eg, routine clinical visits), they might not be representative of the broader US population. Specifically, people who have blood samples taken during routine medical care or sick visits sought health care and had a blood test and thereby may differ in their overall health and disease exposure risk from the general US population [16]. These surveys are unlikely to include populations that traditionally do not seek medical care, that is, younger healthy adults who are also less likely to get tested or get vaccinated. Individuals in the survey may be more likely to have other conditions or exposures that also put them at increased risk for COVID-19, which could result in a higher seroprevalence estimate from the survey population being applied to the general US population in our analysis. However, we were unable to identify another national database that had national

Figure 3. Percentage of the population vaccinated for COVID-19 and/or previously SARS-CoV-2 infected by state as of August 26, 2021. Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
seroprevalence information and was also representative of the entire population.

Second, although we conducted a sensitivity analysis to explore the potential impact of waning immunity, we were unable to more precisely account for waning immunity after infection or vaccination due to a lack of data on date of infection and limited information about duration of natural immunity. Emerging data suggest that immunity due to infection and vaccination may wane over time and may depend on factors including individual characteristics and the SARS-CoV-2 variant. While our results are an optimistic overestimate of immunity (both primary and sensitivity analyses), our use of recent seroprevalence data should be a closer, up-to-date proxy for current immunity in the population (eg, individuals who had antibodies in seroprevalence data closer to infection may no longer have them in recent surveys). Third, to calculate the percentage of the population with immunity, we assumed that immunity due to infection and vaccination were independent. It is possible that vaccination status might vary by infection status, if individuals who had experienced COVID-19 were more or less likely to seek vaccination than those who had not. We were unable to find representative estimates in the literature describing this relationship. Fourth, this was a cross-sectional analysis, conducted at a single point in time, and therefore could not incorporate changes over time or newer emerging variants. A more comprehensive model would be needed to incorporate these additional factors.

Lastly, there are limitations with conducting this analysis at the state level. We were unable to identify relevant seroprevalence estimates by county, and substantial heterogeneity in both disease incidence and vaccine uptake exists for numerous reasons, including population characteristics, population density, and vaccine acceptance. While overall immunity at the larger population levels is critical, the ability to control transmission is also highly dependent on local levels of immunity (eg, within cities and communities). Geographic clustering of low vaccination rates and/or limited natural immunity will provide opportunities for sustained transmission [28–30]. More sophisticated approaches should monitor changes over time.

Figure 4. Percentage of the population vaccinated for COVID-19 and/or previously SARS-CoV-2 infected by state in a sensitivity analysis as of August 26, 2021. Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
and by different levels of geography to help inform vaccination outreach and guide policy decisions. Approaches are also needed that better account for contact patterns to get accurate estimates of the population immunity and the threshold of immunity by which to compare our estimates.

In summary, the percentage of the population with presumed immunity varied substantially across the United States as of August 26, 2021. States with the highest calculated levels of presumed immunity had the highest vaccination rates. In our main analysis, which was the most optimistic scenario, a small number of states had population immunity over the minimum threshold for less infectious variants (67%), but no states were estimated to have reached population immunity using a threshold for more infectious variants (78% or higher) at the time of this analysis. A third or more of the population in all states has neither vaccine-derived nor natural immunity to SARS-CoV-2; therefore, it is imperative that vaccination efforts intensify within all states and that uptake occurs across all ages as soon as vaccines are available. Tracking variation among states and counties is important for public health response and for ensuring that resources are targeted to communities at the highest risk of amplified SARS-CoV-2 transmission. Without increased population immunity, risk of continued transmission and large outbreaks will exist throughout the United States.

Financial support. This work was supported by funding from Pfizer to RTI for data collection, analysis, and manuscript development by Marie Stoner, Sarah Rhea, Linda Brown, and Pia MacDonald, who are employees of RTI.

Potential conflicts of interest. Frederick Angulo, Jessica Atwell, John McLaughlin, Jennifer Nguyen, and David Swerdlow are employees of and hold stock and stock options in Pfizer, Inc. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. M.C.D.S. led the writing and data analysis for the article. All other authors contributed to the design of the study, review of analysis, interpretation of results, and writing, reviewing, and editing the manuscript.

Patient consent. Human subjects were not included in this study, and we used publicly available data. Therefore, our study does not include factors necessitating patient consent.

Acknowledgments

The authors thank Kibri Everett of RTI International for creating the maps used in this article and David Harris and John Forbes of RTI Health Solutions for manuscript review and manuscript editing, respectively.

References

1. Centers for Disease Control and Prevention. COVID Data Tracker. 2021. Available at: https://covid.cdc.gov/covid-data-tracker/#national-lab. Accessed 13 July 2021.

2. World Health Organization. Tracking SARS-CoV-2 variants. 2021. Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed 11 August 2021.

3. Lincoln County Health and Human Services. 2021. CDC update on the COVID-19 pandemic and Delta variant. Available at: https://www.co.lincoln.or.us/hhs/page/cdc-update-covid-19-pandemic-and-delta-variant. Accessed 9 August 2021.

4. Mayo Clinic. Herd immunity and COVID-19 (coronavirus): what you need to know. Available at: https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/herd-immunity-and-coronavirus/art-20468088. Accessed 15 July 2021.

5. Metcalfe CJF, Ferrari M, Graham AL, Grenfell BT. Understanding herd immunity. Trends Immunol 2015; 36:753–5.

6. Kaushal S, Rajput AS, Bhattacharya S, et al. Estimating the herd immunity threshold by accounting for the hidden asymptomatics using a COVID-19 specific model. PLoS One 2020; 15:e0242132.

7. Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol 2020; 20:583–4.

8. Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunol 2020; 52:737–41.

9. Hodgson D, Flasche S, Jt M, Kucharski AJ. Group CC-19 W. The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Euro Surveill 2021; 26:2100428.

10. Dyer O. Covid-19: Delta infections threaten herd immunity vaccine strategy. BMJ 2021; 374:n1933.

11. MacIntyre CR, Costantino V, Trent M. Modelling of COVID-19 vaccination strategies and herd immunity; in scenarios of limited and full vaccine supply in NSW, Australia. Vaccine. 2021;50:264–410(XIV)(20)(0501). 6. doi: 10.1016/j.vaccine.2021.04.042.

12. Map: where people in the U.S. are most vulnerable to the Delta variant. New York Times. 29 July 2021. Available at: https://www.nytimes.com/interactive/2021/07/29/us/delta-variant-risk-map.html?campaign_id=190&femail=edit_uhn_20210802&instance_id=3691316&n=updates-from-the-newsroom&regid=1304184265&segment_id=65151&te=1ruser_id=f0c6ca815a1660016526923f75ce. Accessed 9 August 2021.

13. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 2021; 372:eabg3055.

14. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 infections, symptomatic infections, hospitalizations, and deaths using seroprevalence surveys. JAMA Netw Open 2021; 4:e2033706.

15. Bajgier KL, Wiegard RE, Cuffe K, et al. Estimated SARS-CoV-2 seroprevalence in the US as of September 2020, JAMA Intern Med 2021; 181:450–60.

16. Centers for Disease Control and Prevention. Commercial laboratory seroprevalence surveys | coronavirus | COVID-19. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html. Accessed 20 July 2021.

17. US Census Bureau. 2019 national and state population estimates. 2019. Available at: https://www.census.gov/newsroom/press-kits/2019/national-state-estimates.html. Accessed 2 August 2021.

18. Food and Drug Administration. Janssen COVID-19 vaccine frequently asked questions. 2021. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/janssen-covid-19-vaccine-frequently-asked-questions. Accessed 9 August 2021.

19. Oliver SE. The Advisory Committee on Immunization Practices’ interim recommendation for use of Janssen COVID-19 vaccine — United States, February 2021. MMWR Morb Mortal Wkly Rep 2021; 70:329–32.

20. Baden LR, Sahly HM El, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020; 384:403–16.

21. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15.

22. Haney T, Koch J, Vogen-Ronnel S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill 2021; 26:2100563.

23. Pilishvili T, Fleming-Dutra KE, Farrar J, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel — 33 U.S. sites, January–March 2021. Morb Mortal Wkly Rep 2021; 70:753–8.

24. Tartof SI, Slezak JM, Fisher H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the US: a retrospective cohort study. Lancet 2021; 398:1407–16.

25. Infectious Diseases Society of America. IDSA media briefing: vaccines, the Delta variant, and chasing herd immunity. 2021. Available at: https://www.idsociety.org/ multimedia/videos(idsa-media-briefing-vaccines-the-delta-variant-and-chasing-herd-immunity/. Accessed 9 August 2021.

26. Doucelfel M. Delta variant isn’t as contagious as chickenpox but is still highly contagious. 2021. Available at: https://www.npr.org/sections/goatsandsoda/2021/08/11/1026190062/covid-delta-variant-and-chasing-herd-immunity.

27. US Census Bureau. National population by characteristics: 2010-2019. 2021. Available at: https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-detail.html. Accessed 23 August 2021.

28. Atwell JE, Otterloow JV, Zipprich J, et al. Nonmedical vaccine exemptions and persistent outbreaks in California, 2010. Pediatrics 2013; 132:624–30.

29. Aloe C, Kullendorf M, Bloom BR. Geospatial analysis of nonmedical vaccine exemptions and pertussis outbreaks in the United States. Proc Natl Acad Sci U S A 2017; 114:7101–5.

30. Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA 2016; 315:1149–58.